By: Tanya Thomas on July 12, 2010 at 10:39 AM
Vaccine manufacturers in India and other developing nations can produce a lower-cost HPV vaccine despite the complicated array of patent protections on the technology, according to an Indian-origin scientist at the Duke Institute for Genome Sciences and Policy.
At a cost of at least 300dollars for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil from Merck and Cervarix from GlaxoSmithKline, are some of the most expensive ever introduced.
